Abstract:Abstract Background: Breast cancer (BC) occurs in 1 of 8 women, often requiring debilitating surgery, chemotherapy or radiation for long term survival. Histologic and molecular biomarkers are used to classify BC according to defined subtypes which dictate the choice of targeted therapy or of non-targeted cytotoxic therapy. Despite high initial response rates, relapses are common for more aggressive tumors, and choosing the right therapy for each patient remains challenging. In vitro 3D BC models maintain biologic features that more closely resemble clinical disease than 2D models. However, many 3D models do not contain multiple cell types, are maintained in static culture conditions and rely on immortalized cell lines previously propagated in 2D culture conditions. To address these issues, we developed long term, 3D heterotypic BC microtumors, which recapitulate the dynamic interaction between stromal and epithelial components, retain subtype-specific biomarkers and demonstrate clinically-relevant drug response. We further demonstrated the value of developing non-lytic, label-free in situ analysis to monitor morphology and function of complex 3D microtumors over time. Materials & Methods: Er+, Her2+ or triple negative (TNBC) cell lines (MCF7, SKBR3, MDA-MB-231) or patient derived xenograft (PDX) cells were embedded with human mammary fibroblasts and adipose cells within a hydrogel encapsulated by a silk fibroin scaffold. Microtumors were maintained at least 4 weeks under perfusion flow utilizing the 3DKUBE™ and were characterized for cell morphology and phenotype (IHC), proliferation (PrestoBlue and PicoGreen), gene expression (qRT-PCR), redox ratio (multiphoton microscopy), and biomarker secretion (xMAP® multiplex immunoassay). Drug response profiling (DRP) was performed with tamoxifen, lapatinib and cisplatin. Results: 3D microtumors successfully recapitulated the morphology of primary BC predicted by molecular subtype and gene expression. Perfusion promoted cell proliferation and impacted redox ratio, gene expression, and biomarker secretion in comparison to static culture. Relative redox ratios of 3D microtumors were significantly different from those of cell lines in 2D (p<0.05). Perfusion, 3D conditions, Her2+ and TNBCs were independently associated with increased biomarker secretion, and both cell line and PDX microtumors had unique secretome signatures. PDX microtumors more accurately predicted drug response. Conclusions: Long-term, 3D heterotypic breast microtumors have unique metabolic and secretome signatures which are different than cells in 2D, and the microtumor morphology, metabolism and drug response can be monitored non-destructively in situ. Our ultimate goal is to develop these microtumors using primary human breast tumors for real time drug response profiling in the preclinical, co-clinical and clinical settings to improve outcomes for women with breast cancer. Citation Format: Tessa M. DesRochers, Stephen Shuford, Christina Mattingly, Terri Bruce, Zhiyi Liu, Kyle Quinn, Irene Georgakoudi, David L. Kaplan, David Orr, Howland E. Crosswell. Perfused 3D tri-culture breast cancer microtumors for accurate prediction of drug response. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 320. doi:10.1158/1538-7445.AM2015-320

Enabling high throughput drug discovery in 3D cell cultures through a novel bioprinting workflow

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

Abstract 320: Perfused 3D Tri-Culture Breast Cancer Microtumors for Accurate Prediction of Drug Response

3D Microgroove Electrical Impedance Sensing to Examine 3D Cell Cultures for Antineoplastic Drug Assessment

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

Bioprinting of Novel 3D Tumor Array Chip for Drug Screening

Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications

Pneumatic extrusion bioprinting-based high throughput fabrication of a melanoma 3D cell culture model for anti-cancer drug screening

Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment.

Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry

Microengineering Methods for Cell-Based Microarrays and High-Throughput Drug-Screening Applications

High Throughput Scaffold-Based 3D Micro-Tumor Array for Efficient Drug Screening and Chemosensitivity Testing.

Abstract 2060: Automation of 3D cancer spheroid assay for compound screening

Empowering High Throughput Screening of 3D Models: Automated Dispensing of Cervical and Endometrial Cancer Cells

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

A high-throughput 3D bioprinted cancer cell migration and invasion model with versatile and broad biological applicability

3D Bioprinting of in Vitro Porous Hepatoma Models: Establishment, Evaluation, and Anticancer Drug Testing

Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?

Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening

Abstract 6015: Comprehensive evaluation of three-dimensional (3D) culture systems as compound screening platforms with primary cancer cell lines

In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissues